SG Americas Securities LLC Has $97.74 Million Holdings in Cencora, Inc. $COR

SG Americas Securities LLC lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 2.6% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 311,140 shares of the company’s stock after selling 8,406 shares during the period. SG Americas Securities LLC’s holdings in Cencora were worth $97,742,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AustralianSuper Pty Ltd purchased a new stake in Cencora in the 3rd quarter valued at $26,191,000. Lansforsakringar Fondforvaltning AB publ grew its stake in shares of Cencora by 5.4% in the 3rd quarter. Lansforsakringar Fondforvaltning AB publ now owns 60,254 shares of the company’s stock worth $18,831,000 after acquiring an additional 3,073 shares in the last quarter. Chilton Investment Co. Inc. purchased a new stake in shares of Cencora in the third quarter valued at about $459,000. Nordea Investment Management AB raised its holdings in shares of Cencora by 3.8% in the fourth quarter. Nordea Investment Management AB now owns 1,256,356 shares of the company’s stock valued at $426,715,000 after purchasing an additional 45,712 shares during the last quarter. Finally, Groupama Asset Managment bought a new position in shares of Cencora during the third quarter valued at about $1,225,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

COR has been the topic of several analyst reports. Robert W. Baird cut their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Leerink Partners reissued an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Weiss Ratings downgraded Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. UBS Group upped their target price on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Barclays decreased their price target on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

Cencora Stock Performance

NYSE COR opened at $271.99 on Monday. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The company has a 50-day simple moving average of $284.59 and a 200 day simple moving average of $324.10. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The company has a market capitalization of $52.92 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 1.47 and a beta of 0.59.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the firm earned $4.42 earnings per share. The firm’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, research analysts predict that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio is presently 18.40%.

Cencora announced that its board has initiated a share buyback program on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.